At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 3 enrolled
Drug / intervention
Lenvatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Lenvatinib, and 1 other intervention for Malignant Adrenal Gland Pheochromocytoma and 2 related conditions. Completed, enrolled 3 participants across 1 site.
Detailed Summary
This phase II trial studies how well lenvatinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body or cannot be removed by surgery. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartMay 2017
Primary CompletionDec 2020
Study CompletionSep 2022
TodayJul 2026
First PostedJan 2, 2017
Enrollment StartMay 31, 2017
Primary CompletionDec 1, 2020
Study CompletionSep 28, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 9.5 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Lenvatinibdrug
Given PO
Quality-of-Life Assessmentother
Ancillary studies